Publications
5813 Results
- Journal / Conference
- Cancer Jan 1;131(1):e35560
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID39283236
- PMC
- PMC11834169
Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants
- Journal / Conference
- Journal of the Academy of Nutrition and Dietetics May;125(5):654-665.e3
- Year
- 2025
- Research Committee(s)
- Palliative Care
- PMID
- PMID39603592
- PMC
- PMCIDPMC12009688
- Study Number(s)
- S1316
Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial
- Journal / Conference
- Clinical Cancer Research Jan 17;31(2):308-315
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39561273
- PMC
- PMC11804806
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers
- Journal / Conference
- European Urology Oncology Jun;8(3):612-615
- Year
- 2025
- Research Committee(s)
- Genitourinary
- PMID
- PMID39521639
- PMC
- PMC12059143
- Study Number(s)
- S1216
Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study
- Journal / Conference
- Journal of Clinical Oncology Feb 10;43(5):536-544
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID39671534
- PMC
- PMC11798714
- Study Number(s)
- S1815
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414)
- Journal / Conference
- JNCI-Journal of the National Cancer Institute May 1;117(5):889-897
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID39656951
- PMC
- PMC12058262
- Study Number(s)
- S1007
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007)
- Journal / Conference
- Journal of Thoracic Oncology Mar;20(3):383-394
- Year
- 2025
- Research Committee(s)
- Lung
- PMID
- PMID39505259
- Study Number(s)
- S1929
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
- Journal / Conference
- Journal of Clinical Oncology Apr 10;43(11):1348-1357
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID39761503
- PMC
- PMC11975499
- Study Number(s)
- S1613
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase 2 Trial
- Journal / Conference
- Clinical Trials 2025 Jun;22(3):361-366. doi: 10.1177/17407745241304065. Epub 2025 Jan 15.
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- MYELOMATCH
Evaluating the impact of stratification on the power and cross-arm balance of randomized Phase 2 clinical trials
- Journal / Conference
- Journal of Medical Internet Research vol. 27 | e66821
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- 40053790
- Study Number(s)
- S0307